EUVIMEDEUVIMED entdecken
Open Access

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer

Roberto A Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, Sherene Loi, Vincent de Jong, Jodi M Carter, Torsten O Nielsen, Samuel Leung, Nazia Riaz, Stephen Chia, Gérôme Jules-Clément, Giuseppe Curigliano und 22 weitere

JAMA · 02.04.2024 · 331 (13) · 1135

DOI: 10.1001/jama.2024.3056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 02.04.2024. Verfasst von Roberto A Leon-Ferre und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic, Rochester, Minnesota. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 265-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with adjuvant or neoadjuvant chemotherapy is unclear.

Objective

To study the association of TIL abundance in breast cancer tissue with survival among patients with early-stage TNBC who were treated with locoregional therapy but no chemotherapy. Design, Setting, and Participants Retrospective pooled analysis of individual patient-level data from 13 participating centers in North America (Rochester, Minnesota; Vancouver, British Columbia, Canada), Europe (Paris, Lyon, and Villejuif, France; Amsterdam and Rotterdam, the Netherlands; Milan, Padova, and Genova, Italy; Gothenburg, Sweden), and Asia (Tokyo, Japan; Seoul, Korea), including 1966 participants diagnosed with TNBC between 1979 and 2017 (with follow-up until September 27, 2021) who received treatment with surgery with or without radiotherapy but no adjuvant or neoadjuvant chemotherapy. Exposure TIL abundance in breast tissue from resected primary tumors. Main Outcomes and Measures The primary outcome was invasive disease-free survival [iDFS]. Secondary outcomes were recurrence-free survival [RFS], survival free of distant recurrence [distant RFS, DRFS], and overall survival. Associations were assessed using a multivariable Cox model stratified by participating center.

Results

This study included 1966 patients with TNBC (median age, 56 years [IQR, 39-71]; 55% had stage I TNBC). The median TIL level was 15% (IQR, 5%-40%). Four-hundred seventeen (21%) had a TIL level of 50% or more (median age, 41 years [IQR, 36-63]), and 1300 (66%) had a TIL level of less than 30% (median age, 59 years [IQR, 41-72]). Five-year DRFS for stage I TNBC was 94% (95% CI, 91%-96%) for patients with a TIL level of 50% or more, compared with 78% (95% CI, 75%-80%) for those with a TIL level of less than 30%; 5-year overall survival was 95% (95% CI, 92%-97%) for patients with a TIL level of 50% or more, compared with 82% (95% CI, 79%-84%) for those with a TIL level of less than 30%. At a median follow-up of 18 years, and after adjusting for age, tumor size, nodal status, histological grade, and receipt of radiotherapy, each 10% higher TIL increment was associated independently with improved iDFS (hazard ratio [HR], 0.92 [0.89-0.94]), RFS (HR, 0.90 [0.87-0.92]), DRFS (HR, 0.87 [0.84-0.90]), and overall survival (0.88 [0.85-0.91]) (likelihood ratio test, P < 10e-6). Conclusions and Relevance In patients with early-stage TNBC who did not undergo adjuvant or neoadjuvant chemotherapy, breast cancer tissue with a higher abundance of TIL levels was associated with significantly better survival. These results suggest that breast tissue TIL abundance is a prognostic factor for patients with early-stage TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocytes, Tumor-InfiltratingTriple Negative Breast NeoplasmsAdultHumansMiddle AgedAdjuvants, ImmunologicBritish ColumbiaNeoplasm Recurrence, LocalRetrospective Studies

Substanzen

Adjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Oncology, Mayo Clinic, Rochester, Minnesota.
  • Office of Biostatistics and Epidemiology, Gustave Roussy, Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France.
  • GZA-ZNA-Hospitals, Antwerp, Belgium.
  • Peter Mac Callum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS

Zitieren

APA

Leon-Ferre, R. A., Jonas, S. F., Salgado, R., Loi, S., de Jong, V., Carter, J. M., Nielsen, T. O., Leung, S., Riaz, N., Chia, S., Jules-Clément, G., Curigliano, G., Criscitiello, C., Cockenpot, V., Lambertini, M., Suman, V. J., Linderholm, B., Martens, J. W. M., van Deurzen, C. H. M., …, & International Immuno-Oncology Biomarker Working Group (2024). Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. JAMA, 331(13), 1135. https://doi.org/10.1001/jama.2024.3056

Vancouver

Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, et al. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. JAMA. 2024;331(13):1135. doi:10.1001/jama.2024.3056

BibTeX
@article{LeonFerre2024,
  author = {Leon-Ferre, Roberto A and Jonas, Sarah Flora and Salgado, Roberto and Loi, Sherene and de Jong, Vincent and Carter, Jodi M and Nielsen, Torsten O and Leung, Samuel and Riaz, Nazia and Chia, Stephen and Jules-Clément, Gérôme and Curigliano, Giuseppe and Criscitiello, Carmen and Cockenpot, Vincent and Lambertini, Matteo and Suman, Vera J and Linderholm, Barbro and Martens, John W M and van Deurzen, Carolien H M and Timmermans, A Mieke and Shimoi, Tatsunori and Yazaki, Shu and Yoshida, Masayuki and Kim, Sung-Bae and Lee, Hee Jin and Dieci, Maria Vittoria and Bataillon, Guillaume and Vincent-Salomon, Anne and André, Fabrice and Kok, Marleen and Linn, Sabine C and Goetz, Matthew P and Michiels, Stefan and International Immuno-Oncology Biomarker Working Group, International Immuno-Oncology Biomarker Working Group},
  title = {Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer},
  journal = {JAMA},
  year = {2024},
  volume = {331},
  number = {13},
  pages = {1135},
  doi = {10.1001/jama.2024.3056}
}
Kostenlos starten →